Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended the approval of capvaxive for active immunization for ...

The agency granted priority review to Merck’s application for Welireg (belzutifan ... of the U.S.’ international HIV/AIDs program PEPFAR. JPA Health, a 2024 MM+M Agency 100 honoree, launched an ...

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Robert M Davis, Chairman at Merck & Co (NYSE:MRK). What Happened: Davis's recent move, as outlined in a ...

A significant insider buy by Jennifer Zachary, EVP at Merck & Co MRK, was executed on January 29, and reported in the recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028.

Exclusive-Kennedy Played Key Role in Vaccine Case Against Merck By Dan Levine and Mike Spector (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on Merck (MRK) to $122 from $130 and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ...